Can we learn lessons from the FDA’s approval of aducanumab?
Kathy Liu, Robert Howard
Topics & Concepts
ScrutinyMedicineDrug approvalClinical trialAlternative medicineClinical researchDiseaseFamily medicineDrugPsychiatryLawPathologyPolitical scienceAlzheimer's disease research and treatmentsCholinesterase and Neurodegenerative DiseasesHealth Systems, Economic Evaluations, Quality of Life